[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355741-105":59,"doc-detail-355741-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","health-economic-evaluation-of-mirvetuximab-soravtansine-for-the-treatment-of-fr-positive-platinum-resistant-ovarian-cancer-in-germany","Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany","","Purpose: Mirvetuximab soravtansine (MIRV) is an antibody–drug conjugate targeting folate receptor α (FRα), approved for FRα-positive, platinum-resistant ovarian cancer. This study performs a health economic evaluation of MIRV from the perspective of the statutory health insurance in Germany. Methods and findings: A Markov model with stable, progressive, and dead states over five years uses transition probabilities from MIRASOL Kaplan–Meier curves, applying direct costs and literature-based utilities. Costs and outcomes are summarized with ICER and ICUR, supported by deterministic and probabilistic sensitivity analyses. Results: MIRV adds 0.408 life years and 0.226 QALYs at incremental costs of €128,338.84, yielding ICER €314,753.36 per LY and ICUR €567,734.77 per QALY. Threshold exceedance occurs in scenarios, mainly driven by drug price. Conclusion: MIRV is likely more effective, but not cost-effective without drug price reduction in Germany.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/health-economic-evaluation-of-mirvetuximab-soravtansine-for-the-treatment-of-fr-positive-platinum-resistant-ovarian-cancer-in-germany/355741/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/health-economic-evaluation-of-mirvetuximab-soravtansine-for-the-treatment-of-fr-positive-platinum-resistant-ovarian-cancer-in-germany/355741.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study purpose of MIRV health economic evaluation?","Question",{"text":113,"@type":114},"To assess the health economic value of mirvetuximab soravtansine (MIRV) for FRα-positive, platinum-resistant ovarian cancer from the German statutory health insurance perspective.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were clinical outcomes translated into economic results?",{"text":118,"@type":114},"A five-year Markov state-transition model with stable, progressive, and dead states used transition probabilities derived from MIRASOL Kaplan–Meier survival curves, combined with direct costs and literature-based utilities.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main cost-effectiveness results in the base case?",{"text":122,"@type":114},"MIRV produced incremental gains of 0.408 life years and 0.226 QALYs versus standard therapy, with incremental costs of €128,338.84; ICER was €314,753.36 per LY and ICUR was €567,734.77 per QALY.",{"name":124,"@type":111,"acceptedAnswer":125},"Why is MIRV unlikely to be considered cost-effective in Germany?",{"text":126,"@type":114},"Although scenarios exceeded the defined threshold, the drug price had the greatest influence, so cost-effectiveness would require a reduction in the MIRV price in the German healthcare context.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},355741,1790183260,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":41,"preview_page_count":19,"preview_urls":150},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Journal of Cancer Research and Clinical Oncology (2026) 152:111  \n[https://doi.org/10.1007/s00432-026-06488-8](https://doi.org/10.1007/s00432-026-06488-8)  \nRESEARCH  \nHealth economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany  \nFranz F. Janke1 · Ross J. Baldessarini2,3 · Dirk Bauerschlag4 · Stefanie Zibolka5 · Michael Hartmann1  \nReceived: 7 February 2026 / Accepted: 17 April 2026 © The Author(s) 2026  \nAbstract  \nPurpose Mirvetuximab soravtansine (MIRV) is an antibody–drug conjugate targeting the folate receptor α (FRα), approved for FRα-positive platinum-resistant ovarian cancer based on improved progression-free and overall survival and higher response rates compared with standard therapy in the MIRASOL trial. The aim of the present study was to provide a health economic evaluation of MIRV from the perspective of the statutory health insurance in Germany.  \nMethods and findings A Markov state-transition model with three health states (stable, progressive, dead) was used with a time horizon of fives years. Transition probabilities were derived from published Kaplan–Meier survival curves of the MIRASOL trial. Direct costs and literature-based utilities were applied. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER) and the incremental cost-utility ratio (ICUR) . Deterministic and probabilistic sensitivity analyses addressed the uncertainty of the model. In the base case, MIRV resulted in an incremental gain of 0.408 life years (LYs) or 0.226 quality-adjusted life years (QALYs) compared to standard therapy. Incremental costs of €128,338.84 were incurred. This resulted in an ICER of €314,753.36 per additional LYs and €567,734.77 per QALY. All analyzed scenarios exceeded the defined threshold, of three times the German gross domestic product per capita, with the drug price having the greatest influence.  \nConclusion MIRV is highly likely to be a more effective treatment option than the chemotherapies currently available for patients with FRα-positive, platinum-resistant ovarian cancer, as approximately 75–90% of ovarian cancers are FRα -positive. However, in the current circumstances, MIRV is unlikely to be considered cost-effective within the German healthcare context without reduction in the drug price.  \nKeywords Cost-effectiveness analysis · Economic evaluation · Health economics · Markov model · Mirvetuximabsoravtansine · Platinum-resistant ovarian cancer  \n􀀍 Franz F. Janke [franzferdinand.janke@med.uni-jena.de](franzferdinand.janke@med.uni-jena.de)  \n1 Institute for Hospital Pharmacy, Jena University Hospital, Jena, Germany  \n2 International Consortium for Mood and Psychotic Disorder Research, Mailman Research Center, McLean Hospital, Belmont, MA, USA  \n3 Department of Psychiatry, Harvard Medical School, Boston, MA, USA  \n4 Department for Gynecology and Reproductive Medicine, Jena University Hospital, Jena, Germany  \n5 Central Pharmacy, Magdeburg University Hospital, Magdeburg, Germany  \nIntroduction  \nIn Germany, around 7,200 women are diagnosed with ovarian cancer each year, corresponding to lifetime risk of approximately 1:74 (DKR 2023; International Agency for Research on Cancer 2024a) . Ovarian cancer accounts for about one-third of all malignant neoplasms of the female genital tract but causes half of all deaths from such tumors (DKR 2023) . Despite declining incidence and mortality rates, the prognosis remains poor, as 73% of diagnosis are made at an advanced stage (FIGO III/IV) (DKR 2023) . The relative 5-year survival rate decreases with advancing stage at diagnosis and is 43% in stage III and only 21% in stage IV (DKR 2023) . Mortality is also high globally, which is due,  \namong other things, to late diagnoses and limited access to modern targeted therapies (DKR 2023) .  \nOvarian cancer is the third most common fatal gynecological tumor disease after breast and cervical cancer (International Agency f","cbCaikGf0LE7mNLn","https://ap.wps.com/l/cbCaikGf0LE7mNLn","pdf",1543252,12,"English","# Abstract\n## Purpose\n## Methods and findings\n## Results\n## Conclusion\n# Introduction\n## Disease burden and unmet need\n## Target and mechanism of MIRV\n## Evidence from MIRASOL trial","[{\"question\":\"What is the study purpose of MIRV health economic evaluation?\",\"answer\":\"To assess the health economic value of mirvetuximab soravtansine (MIRV) for FRα-positive, platinum-resistant ovarian cancer from the German statutory health insurance perspective.\"},{\"question\":\"How were clinical outcomes translated into economic results?\",\"answer\":\"A five-year Markov state-transition model with stable, progressive, and dead states used transition probabilities derived from MIRASOL Kaplan–Meier survival curves, combined with direct costs and literature-based utilities.\"},{\"question\":\"What were the main cost-effectiveness results in the base case?\",\"answer\":\"MIRV produced incremental gains of 0.408 life years and 0.226 QALYs versus standard therapy, with incremental costs of €128,338.84; ICER was €314,753.36 per LY and ICUR was €567,734.77 per QALY.\"},{\"question\":\"Why is MIRV unlikely to be considered cost-effective in Germany?\",\"answer\":\"Although scenarios exceeded the defined threshold, the drug price had the greatest influence, so cost-effectiveness would require a reduction in the MIRV price in the German healthcare context.\"}]","Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany | PDF",1790120723,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a23b74e2422bd80efddea39ee7bd0f8d.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fa0516a54831a3a4d4f07f2e0a2992e.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d6bd36eaf7e4f12120add0477b5bf09.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f650c30391aed613f4c896b097e8b97d.webp",980,1301]